Taro Pharmaceuticals Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
$1.6B
Website
Clinical Trials
Related News

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Placebo
Drug: Aczone
Drug: DPSG 7.5%
First Posted Date
2017-04-27
Last Posted Date
2017-05-04
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
1125
Registration Number
NCT03132194

To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

First Posted Date
2017-03-29
Last Posted Date
2024-04-10
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
1000
Registration Number
NCT03094403

Efficacy Study in Patients With Acne Vulgaris.

First Posted Date
2016-10-17
Last Posted Date
2018-10-18
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
294
Registration Number
NCT02935036

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Phase 3
Completed
Conditions
Scalp Psoriasis
Interventions
Drug: DSXS topical
Drug: Vehicle topical
First Posted Date
2016-10-14
Last Posted Date
2018-12-06
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
371
Registration Number
NCT02933866
Locations
🇺🇸

Taro Pharmaceuticals USA, Inc., Hawthorne, New York, United States

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: DSXS Topical product
First Posted Date
2016-10-14
Last Posted Date
2018-12-06
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
24
Registration Number
NCT02933528
Locations
🇺🇸

Taro Pharmaceuticals USA, Inc., Hawthorne, New York, United States

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

First Posted Date
2016-10-14
Last Posted Date
2018-12-20
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
184
Registration Number
NCT02933879
Locations
🇺🇸

Novum Pharmaceutical Research Services (Novum), Pittsburgh, Pennsylvania, United States

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Phase 2
Completed
Conditions
Scalp Psoriasis
Interventions
Drug: DSXS topical product
First Posted Date
2016-10-14
Last Posted Date
2018-12-10
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
3
Registration Number
NCT02933502
Locations
🇺🇸

Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

Phase 3
Completed
Conditions
Scalp Psoriasis
Interventions
Drug: DSXS
Drug: Placebo
First Posted Date
2016-10-13
Last Posted Date
2018-12-06
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
373
Registration Number
NCT02932462

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: DSXS topical
First Posted Date
2016-10-13
Last Posted Date
2018-12-07
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
28
Registration Number
NCT02932891
Locations
🇺🇸

Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: DSXS topical
First Posted Date
2016-10-13
Last Posted Date
2018-12-06
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
16
Registration Number
NCT02932878
Locations
🇺🇸

Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy